Metastatic perivascular epithelioid cell tumor responding to mammalian target of rapamycin inhibition

Indian Journal of Medical and Paediatric Oncology

Volumn 35, Issue 1, 2014, Pages 99-102

  Ghosh, Indranil ^a   Arun, Indu ^a   Sen, Saugata ^a   Mishra, Lopamudra ^a  

^a TATA MEDICAL CENTER   (India)

Author keywords

Immunohistochemistry; Mammalian target of rapamycin inhibitors; Perivascular epithelioid cell tumors; Temsirolimus

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; RAPAMYCIN; TEMSIROLIMUS;

ABDOMINAL PAIN; ADULT; ARTICLE; CANCER PROGNOSIS; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DRUG WITHDRAWAL; EDEMA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; IMMUNOHISTOCHEMISTRY; LAPAROTOMY; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; OMENTECTOMY; ORAL MUCOSITIS; PELVIS; PERIVASCULAR EPITHELIOID CELL TUMOR; PRIORITY JOURNAL;

EID: 84902151347     PISSN: 09715851     EISSN: 09752129     Source Type: Journal    
DOI: 10.4103/0971-5851.133733     Document Type: Article

References (12)

1. Folpe AL. Neoplasms with perivascular epithelioid cell differentiation (PEComas). In: Fletcher CD, Unni KK, Mertens F, editors. World Health Organization Classification of Tumors: Pathology and Genetics of Tumors of Soft Tissue and Bone. Lyon: IARC Press; 2002. p. 221-2.
2. Bleeker JS, Quevedo JF, Folpe AL. "Malignant" perivascular epithelioid cell neoplasm: Risk stratification and treatment strategies. Sarcoma 2012;2012:541626.
3. Folpe AL, Mentzel T, Lehr HA, Fisher C, Balzer BL, Weiss SW. Perivascular epithelioid cell neoplasms of soft tissue and gynecologic origin: A clinicopathologic study of 26 cases and review of the literature. Am J Surg Pathol 2005;29:1558-75.
4. Wagner AJ, Malinowska-Kolodziej I, Morgan JA, Qin W, Fletcher CD, Vena N, et al.. Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: Targeting the pathogenic activation of mTORC1 in tumors. J Clin Oncol 2010;28:835-40.
5. Subbiah V, Trent JC, Kurzrock R. Resistance to mammalian target of rapamycin inhibitor therapy in perivascular epithelioid cell tumors. J Clin Oncol 2010;28:e415.
6. Italiano A, Delcambre C, Hostein I, Cazeau AL, Marty M, Avril A, et al.. Treatment with the mTOR inhibitor temsirolimus in patients with malignant PEComa. Ann Oncol 2010;21:1135-7.
7. Ross C, Sharma S, Louca O, Scurr M, Hayes A, Judson I. A patient presenting with a perivascular epithelioid cell tumor in the broad ligament: A case report. J Med Case Rep 2011;5:383.
8. Quek R, Wang Q, Morgan JA, Shapiro GI, Butrynski JE, Ramaiya N, et al.. Combination mTOR and IGF-1R inhibition: Phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors. Clin Cancer Res 2011;17:871-9.
9. Gennatas C, Michalaki V, Kairi PV, Kondi-Paphiti A, Voros D. Successful treatment with the mTOR inhibitor everolimus in a patient with perivascular epithelioid cell tumor. World J Surg Oncol 2012;10:181.
10. Pedersen JV, Benson C, Tunariu N, Mitchell S, Fisher C, Thway K, et al.. A retrospective study from the Royal Marsden Hospital (RMH) of patients with malignant perivascular epithelioid cell tumors (PEComa) receiving treatment with sirolimus (SI) or temsirolimus (TSI). J Clin Oncol 2012;30 Suppl: Abstr 10038.
11. Dickson MA, Schwartz GK, Antonescu CR, Kwiatkowski DJ, Malinowska IA. Extrarenal perivascular epithelioid cell tumors (PEComas) respond to mTOR inhibition: Clinical and molecular correlates. Int J Cancer 2013;132:1711-7.
12. Scheppach W, Reissmann N, Sprinz T, Schippers E, Schoettker B, Mueller JG. PEComa of the colon resistant to sirolimus but responsive to doxorubicin/ifosfamide. World J Gastroenterol 2013;19:1657-60.